Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 27 04:00PM ET
37.00
Dollar change
-0.61
Percentage change
-1.62
%
Index- P/E- EPS (ttm)-75.06 Insider Own11.04% Shs Outstand36.06M Perf Week-6.94%
Market Cap1.34B Forward P/E- EPS next Y-2.95 Insider Trans0.00% Shs Float32.16M Perf Month48.53%
Income-338.79M PEG- EPS next Q-1.03 Inst Own70.21% Short Float8.95% Perf Quarter91.71%
Sales0.89M P/S1502.87 EPS this Y93.18% Inst Trans-13.98% Short Ratio6.06 Perf Half Y226.57%
Book/sh-0.03 P/B- EPS next Y11.82% ROA-164.06% Short Interest2.88M Perf Year385.09%
Cash/sh9.39 P/C3.94 EPS next 5Y- ROE-289.17% 52W Range2.66 - 47.97 Perf YTD71.93%
Dividend Est.- P/FCF- EPS past 5Y1.60% ROI-126.15% 52W High-22.87% Beta2.88
Dividend TTM- Quick Ratio10.68 Sales past 5Y-49.91% Gross Margin-8.80% 52W Low1290.98% ATR (14)3.53
Dividend Ex-Date- Current Ratio10.68 EPS Y/Y TTM-167.27% Oper. Margin-14510.61% RSI (14)53.06 Volatility8.87% 11.11%
Employees30 Debt/Eq0.46 Sales Y/Y TTM-61.96% Profit Margin-38238.15% Recom1.00 Target Price40.00
Option/ShortNo / Yes LT Debt/Eq0.46 EPS Q/Q43.78% Payout- Rel Volume1.23 Prev Close37.61
Sales Surprise-100.00% EPS Surprise-456.93% Sales Q/Q-100.00% EarningsFeb 29 AMC Avg Volume474.94K Price37.00
SMA20-3.08% SMA5023.95% SMA200111.95% Trades Volume573,502 Change-1.62%
Date Action Analyst Rating Change Price Target Change
Mar-01-24Upgrade Wells Fargo Equal Weight → Overweight $12 → $35
Dec-20-23Initiated BTIG Research Buy $32
Dec-11-23Initiated Jefferies Buy $31
Dec-11-23Initiated Guggenheim Buy $44
May-04-20Initiated Piper Sandler Overweight $12
Mar-21-19Initiated JP Morgan Overweight $14
Sep-04-18Downgrade Wells Fargo Outperform → Market Perform
Apr-24-18Initiated Evercore ISI Outperform $37
Mar-14-18Reiterated Needham Buy $8 → $12
Mar-18-24 08:00AM
Mar-04-24 08:50AM
Mar-01-24 05:25PM
Feb-29-24 04:05PM
Feb-26-24 07:30AM
07:30AM Loading…
Feb-08-24 07:30AM
Feb-06-24 09:55AM
Feb-05-24 07:30AM
Feb-02-24 05:30PM
Dec-22-23 05:00PM
Dec-08-23 07:19AM
Dec-07-23 06:20PM
Nov-28-23 08:00AM
Nov-27-23 08:30AM
Nov-22-23 05:00PM
06:26PM Loading…
Nov-09-23 06:26PM
04:05PM
Nov-03-23 05:00PM
Oct-30-23 08:00PM
Oct-02-23 06:02PM
Sep-14-23 05:03PM
Sep-07-23 08:40AM
Sep-05-23 07:00AM
Aug-11-23 07:07AM
07:00AM
Jul-27-23 07:00AM
Jun-23-23 04:30PM
10:31AM
Jun-22-23 10:59AM
08:17AM
08:03AM Loading…
May-13-23 08:03AM
May-11-23 08:15AM
07:10AM
07:01AM
Apr-13-23 09:44AM
Apr-12-23 07:00AM
Mar-17-23 05:30PM
Mar-02-23 10:15AM
07:01AM
Feb-12-23 07:40AM
Jan-06-23 07:01AM
Jan-02-23 07:29AM
Dec-14-22 12:00PM
Dec-02-22 04:05PM
Nov-30-22 10:38AM
07:01AM
Nov-15-22 04:25PM
Nov-03-22 08:35AM
07:01AM
Oct-21-22 12:27PM
12:06PM
Oct-19-22 04:05PM
Oct-17-22 11:57AM
Oct-04-22 11:05AM
07:01AM
Aug-29-22 04:05PM
Aug-27-22 09:18AM
Aug-25-22 11:52AM
Aug-24-22 12:40PM
08:01AM
Aug-22-22 12:28PM
Aug-20-22 10:49AM
Aug-19-22 06:26AM
Aug-18-22 04:05PM
Aug-04-22 08:35AM
07:01AM
Jul-24-22 10:41AM
Jul-08-22 11:14AM
Jul-07-22 11:22AM
Jul-04-22 11:49AM
Jun-29-22 12:34PM
Jun-28-22 11:52AM
10:23AM
Jun-13-22 12:01PM
Jun-09-22 09:56AM
Jun-03-22 10:49AM
Jun-02-22 03:26PM
03:20PM
12:09PM
11:24AM
08:59AM
Jun-01-22 02:25PM
02:22PM
May-31-22 11:26AM
May-26-22 11:18AM
May-25-22 12:07PM
May-23-22 11:46AM
11:33AM
May-20-22 09:50AM
May-18-22 11:47AM
11:03AM
May-17-22 11:31AM
May-13-22 10:30AM
May-11-22 09:47AM
May-05-22 09:28AM
07:45AM
06:30AM
Apr-13-22 12:42PM
Apr-12-22 08:10AM
06:01AM
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.